Suche klinische Studie
Weitere Suchoptionen
8 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
PREVEnt: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) - BE
Institution: Information not provided - BE
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
PREVEnt: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) -FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
VETCOSED: Effectiveness of Wearing a Compression Garment (SED CICATREX® Model) for Patients With Hypermobility Type of Ehlers-Danlos Syndrome
Centre Médico-Chirurgical de Réadaptation des Massues - Croix-Rouge française
Médecine physique et réadaptation Adultes
FRANKREICH
GRAND-EST
VANDOEUVRE-LÈS-NANCY
NOVASED: Efficiency Clinical Study of NOVATEX MEDICAL Compression Garments in Patients With Ehlers-Danlos Syndrome.
CHU de Nancy - Hôpitaux de Brabois
Service de médecine interne et immunologie clinique
FRANKREICH
ILE-DE-FRANCE
PARIS
ARCADE: Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial (Phase III) - FR
AP-HP. Centre - Université de Paris - HEGP Hôpital Européen Georges Pompidou
Service de génétique - CR des Maladies Vasculaires Rares
VEREINIGTE STAATEN
Colorado
ENGLEWOOD
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB
PREVEnt: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) -GB
Institution: Information not provided - GB
Multinationale klinische Studie(n)
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US